Compare STG & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STG | ECOR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.3M | 50.0M |
| IPO Year | 2017 | 2018 |
| Metric | STG | ECOR |
|---|---|---|
| Price | $4.40 | $6.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 2.5K | ★ 46.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.51 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,182,000.00 |
| Revenue This Year | N/A | $28.92 |
| Revenue Next Year | N/A | $32.50 |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | ★ 57.09 |
| 52 Week Low | $4.28 | $4.16 |
| 52 Week High | $15.00 | $9.22 |
| Indicator | STG | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 42.70 |
| Support Level | $4.28 | $4.64 |
| Resistance Level | $4.87 | $8.02 |
| Average True Range (ATR) | 0.13 | 0.71 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 14.56 | 5.42 |
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.